Q32 Bio alerts on release of SIGNAL-AA bempikibart trial results update

• Q32 Bio posted positive 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata.
• Primary endpoint showed a 35.3% mean reduction in SALT score from baseline in the prespecified mITT analysis.
• SALT-20 response reached 40% in mITT, 30.3% in ITT; safety was generally well tolerated with no new signals.
• Company targets a registration-directed program in the first half of 2027; release available at https://www.q32bio.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-301464), on July 13, 2026, and is solely responsible for the information contained therein.